Literature DB >> 9270669

Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis.

K R Mills1, K A Nithi.   

Abstract

The pathogenesis of idiopathic amyotrophic lateral sclerosis (ALS) remains unknown, but accumulating evidence suggests a neuroexcitotoxic mechanism may have some credence. Glutamate-induced hyperexcitability of cortical or spinal motoneurons may be expected to manifest itself as a reduced threshold for activation of these structures. We have measured corticomotor threshold to the first dorsal interosseous (FDI) muscles of 48 patients with sporadic ALS using magnetic brain stimulation and have correlated the findings with physical signs of upper and/or lower motor neuron degeneration. We find that if FDI in patients with ALS shows no weakness, wasting, or signs of an upper motor neuron lesion, mean corticomotor threshold is significantly lower than in 102 healthy control FDI muscles (P = 0.02). In contrast, FDI muscles showing signs of lower motor neuron degeneration only or mixed upper and lower motor neuron signs are associated with a raised corticomotor threshold (P = 0.008, P < 0.001, respectively). We conclude that early in ALS, at a time when hand muscle function is normal, corticomotor threshold is reduced and suggest that this may be a manifestation of abnormal excitability of cortical or spinal motoneurons to neurotransmitters, whose action will ultimately lead to cell death.

Entities:  

Mesh:

Year:  1997        PMID: 9270669     DOI: 10.1002/(sici)1097-4598(199709)20:9<1137::aid-mus7>3.0.co;2-9

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  38 in total

Review 1.  Positive muscle phenomena--diagnosis, pathogenesis and associated disorders.

Authors:  Hans G Kortman; Jan H Veldink; Gea Drost
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

Review 2.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

3.  A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.

Authors:  Michael D Weiss; Eric A Macklin; Zachary Simmons; Angela S Knox; David J Greenblatt; Nazem Atassi; Michael Graves; Nicholas Parziale; Johnny S Salameh; Colin Quinn; Robert H Brown; Jane B Distad; Jaya Trivedi; Jeremy M Shefner; Richard J Barohn; Alan Pestronk; Andrea Swenson; Merit E Cudkowicz
Journal:  Neurology       Date:  2016-02-24       Impact factor: 9.910

4.  Superconditioning TMS for examining upper motor neuron function in MND.

Authors:  Blair Calancie; Eufrosina Young; Mary Lou Watson; Dongliang Wang; Natalia Alexeeva
Journal:  Exp Brain Res       Date:  2019-06-07       Impact factor: 1.972

Review 5.  Impairments in Motor Neurons, Interneurons and Astrocytes Contribute to Hyperexcitability in ALS: Underlying Mechanisms and Paths to Therapy.

Authors:  Dzung Do-Ha; Yossi Buskila; Lezanne Ooi
Journal:  Mol Neurobiol       Date:  2017-02-03       Impact factor: 5.590

Review 6.  Cortical excitability and neurology: insights into the pathophysiology.

Authors:  Radwa A B Badawy; Tobias Loetscher; Richard A L Macdonell; Amy Brodtmann
Journal:  Funct Neurol       Date:  2012 Jul-Sep

Review 7.  Neurophysiological markers of network dysfunction in neurodegenerative diseases.

Authors:  Roisin McMackin; Peter Bede; Niall Pender; Orla Hardiman; Bahman Nasseroleslami
Journal:  Neuroimage Clin       Date:  2019-02-02       Impact factor: 4.881

Review 8.  Quo vadis motor neuron disease?

Authors:  Rubika Balendra; Rickie Patani
Journal:  World J Methodol       Date:  2016-03-26

Review 9.  Stronger is not always better: could a bodybuilding dietary supplement lead to ALS?

Authors:  Marin Manuel; C J Heckman
Journal:  Exp Neurol       Date:  2010-12-15       Impact factor: 5.330

10.  Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS.

Authors:  M R Turner; A D Osei-Lah; A Hammers; A Al-Chalabi; C E Shaw; P M Andersen; D J Brooks; P N Leigh; K R Mills
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.